Safety and Efficacy of CD22 and CD19 Chimeric Antigen Receptor T Cell Treatment Bridging to Autologous Stem Cell Transplantation As Consolidation Therapy for B-Cell Acute Lymphoblastic Leukemia

被引：0
|
作者：
Qiu, Yan [1 ]
Qian, Chong-Sheng [1 ]
Zhou, Hai-Xia [1 ]
Xu, Ming-Zhu [1 ]
Kang, Li-Qing [2 ]
Sun, Ai-Ning [1 ]
Wu, De-Pei [1 ]
Yu, Lei [2 ]
Xue, Shengli [1 ]
机构：
[1] Soochow Univ, Affiliated Hosp 1, Suzhou, Peoples R China
[2] Shanghai Unicar Therapy Biomed Technol Co Ltd, Shanghai, Peoples R China
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-164636
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：10337 / 10338
页数：2
相关论文
共 50 条
  • [21] Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract
    Zeng, Chen
    Cheng, Jiali
    Li, Tongjuan
    Huang, Jin
    Li, Chunrui
    Jiang, Lijun
    Wang, Jue
    Chen, Liting
    Mao, Xia
    Zhu, Li
    Lou, Yaoyao
    Zhou, Jianfeng
    Zhou, Xiaoxi
    CYTOTHERAPY, 2020, 22 (03) : 166 - 171
  • [22] CD19/CD22 dual-targeting chimeric antigen receptor T-cell therapy bridging to allogeneic haematopoietic stem cell transplantation for B-cell acute lymphoblastic leukaemia delays platelet recovery and increases risks of cytomegalovirus and Epstein-Barr virus viremia after transplantation
    Li, Shijia
    Ge, Jianrong
    Zhou, Shiyuan
    Zhu, Wenjuan
    Han, Yue
    Chen, Suning
    Xue, Shengli
    Wang, Ying
    Qiu, Huiying
    Wu, Xiaojin
    Wu, Depei
    CLINICAL AND TRANSLATIONAL MEDICINE, 2023, 13 (10):
  • [23] Efficacy and Safety of Chimeric Antigen Receptor T Cells Therapy Strategy That Dual Targeting CD19 and CD22 to Treat Relapsed/Refractory Acute Lymphoblastic Leukemia in Adults
    Tu, Sanfang
    Zhou, Lijuan
    Huang, Rui
    Zhou, Xuan
    Yang, Jilong
    Li, Meifang
    Jin, Bo
    Wang, Langqi
    Zhuo, Yaqi
    Chen, Huifang
    Chang, Lung-Ji
    Li, Yuhua
    BLOOD, 2023, 142
  • [24] CD19/CD22 CAR-T Cell Cocktail Therapy Following Autologous Transplantation in Patients with Relapsed/Refractory B-Cell Lymphomas
    Cao, Yang
    Xiao, Yi
    Wang, Na
    Wang, Gaoxiang
    Zhou, Xiaoxi
    Huang, Liang
    Chen, Liting
    Xiao, Min
    Zhang, Tongcun
    Zhang, Yicheng
    Zhou, Jianfeng
    BLOOD, 2020, 136
  • [25] Impact of tocilizumab on anti-CD19 chimeric antigen receptor T-cell therapy in B-cell acute lymphoblastic leukemia
    Wang, Xiangmin
    Zhang, Bingpei
    Zhang, Qing
    Zhou, Hongyuan
    Sun, Qian
    Zhou, Yi
    Li, Tianci
    Zhou, Dian
    Shen, Ziyuan
    Zhang, Jiaoli
    Li, Ping
    Liang, Aibin
    Zhou, Keshu
    Han, Lu
    Hu, Yongxian
    Yang, Yun
    Cao, Jiang
    Li, Zhenyu
    Xu, Kailin
    Sang, Wei
    CANCER, 2024, 130 (15) : 2660 - 2669
  • [26] Feasibility and Safety of CD19 Chimeric Antigen Receptor T Cell Treatment for B Cell Lymphoma Relapse after Allogeneic Hematopoietic Stem Cell Transplantation
    Schubert, Maria-Luisa
    Dietrich, Sascha
    Stilgenbauer, Stephan
    Schmitt, Anita
    Pavel, Petra
    Kunz, Alexander
    Bondong, Andrea
    Wegner, Mandy
    Stadtherr, Peter
    Jung, Susanne
    Ho, Anthony D.
    Mueller-Tidow, Carsten
    Schmitt, Michael
    Dreger, Peter
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (09) : 1575 - 1580
  • [27] Effectiveness and safety of CD22 and CD19 dual-targeting chimeric antigen receptor T-cell therapy in patients with relapsed or refractory B-cell malignancies: A meta-analysis
    Nguyen, Thi Thuy
    Thanh Nhu, Nguyen
    Chen, Chia-Ling
    Lin, Chiou-Feng
    CANCER MEDICINE, 2023, 12 (18): : 18767 - 18785
  • [28] Outcomes of CD19 chimeric antigen receptor T cell followed by haploidentical hematopoietic stem-cell transplantation in relapsed/refractory B-cell acute lymphoblastic leukemia with IKZF1 deletion
    Ni, Fang
    Yin, Elaine Tan Su
    Zhou, Linghui
    Zhao, Houli
    Luo, Yi
    Shi, Jimin
    Hu, Yongxian
    Huang, He
    BONE MARROW TRANSPLANTATION, 2022, 57 (02) : 326 - 328
  • [29] Outcomes of CD19 chimeric antigen receptor T cell followed by haploidentical hematopoietic stem-cell transplantation in relapsed/refractory B-cell acute lymphoblastic leukemia with IKZF1 deletion
    Fang Ni
    Elaine Tan Su Yin
    Linghui Zhou
    Houli Zhao
    Yi Luo
    Jimin Shi
    Yongxian Hu
    He Huang
    Bone Marrow Transplantation, 2022, 57 : 326 - 328
  • [30] CD22 Gating for Flow Cytometric Analysis in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia after CD19 CAR-T Therapy
    Yu, Xinjian
    Li, Pan
    Feng, Heyuan
    Kang, Jian
    Zheng, Xichang
    Zhang, Yunmei
    Yang, Wenhong
    Wu, Tong
    Liu, Shuangyou
    BLOOD, 2020, 136
12345